SARS-CoV-2 诊断、治疗和疫苗配方的最新进展:纳米技术在战略性抗击 COVID-19 大流行中的新范例。

Q1 Biochemistry, Genetics and Molecular Biology
Current Pharmacology Reports Pub Date : 2021-01-01 Epub Date: 2021-02-03 DOI:10.1007/s40495-021-00250-z
Sushil Kumar Upadhyay, Siddhartha Dan, Mansi Girdhar, Kartikey Rastogi
{"title":"SARS-CoV-2 诊断、治疗和疫苗配方的最新进展:纳米技术在战略性抗击 COVID-19 大流行中的新范例。","authors":"Sushil Kumar Upadhyay, Siddhartha Dan, Mansi Girdhar, Kartikey Rastogi","doi":"10.1007/s40495-021-00250-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>The coronavirus disease-2019 (COVID-19) is a global pandemic which has not been seen in recent history, leaving behind deep socioeconomic damages and huge human losses with the disturbance in the healthcare sector. Despite the tremendous international effort and the launch of various clinical trials for the containment of this pandemic, no effective therapy has been proven yet.</p><p><strong>Recent findings: </strong>This review has highlighted the different traditional therapeutic techniques, along with the potential contribution of nanomedicine against the severe acute respiratory syndrome corovirus-2 (SARS-CoV-2). Repositioning of the drugs, such as remdesivir and chloroquine, is a rapid process for the reach of safe therapeutics, and the related clinical trials have determined effects against COVID-19. Various protein-based SARS-CoV-2 vaccine candidates have successfully entered clinical phases, determining positive results. The self-assembled and metallic nanovaccines mostly based on the antigenic properties of spike (S) protein are also approachable, feasible, and promising techniques for lowering the viral burden.</p><p><strong>Summary: </strong>There are number of NP-based diagnostic systems have been reported for coronaviruses (CoVs) and specifically for SARS-CoV-2. However, extensive studies are still necessary and required for the nanoparticle (NP)-based therapy.</p>","PeriodicalId":11139,"journal":{"name":"Current Pharmacology Reports","volume":"7 1","pages":"1-14"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854874/pdf/","citationCount":"0","resultStr":"{\"title\":\"Recent Advancement in SARS-CoV-2 Diagnosis, Treatment, and Vaccine Formulation: a New Paradigm of Nanotechnology in Strategic Combating of COVID-19 Pandemic.\",\"authors\":\"Sushil Kumar Upadhyay, Siddhartha Dan, Mansi Girdhar, Kartikey Rastogi\",\"doi\":\"10.1007/s40495-021-00250-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose of review: </strong>The coronavirus disease-2019 (COVID-19) is a global pandemic which has not been seen in recent history, leaving behind deep socioeconomic damages and huge human losses with the disturbance in the healthcare sector. Despite the tremendous international effort and the launch of various clinical trials for the containment of this pandemic, no effective therapy has been proven yet.</p><p><strong>Recent findings: </strong>This review has highlighted the different traditional therapeutic techniques, along with the potential contribution of nanomedicine against the severe acute respiratory syndrome corovirus-2 (SARS-CoV-2). Repositioning of the drugs, such as remdesivir and chloroquine, is a rapid process for the reach of safe therapeutics, and the related clinical trials have determined effects against COVID-19. Various protein-based SARS-CoV-2 vaccine candidates have successfully entered clinical phases, determining positive results. The self-assembled and metallic nanovaccines mostly based on the antigenic properties of spike (S) protein are also approachable, feasible, and promising techniques for lowering the viral burden.</p><p><strong>Summary: </strong>There are number of NP-based diagnostic systems have been reported for coronaviruses (CoVs) and specifically for SARS-CoV-2. However, extensive studies are still necessary and required for the nanoparticle (NP)-based therapy.</p>\",\"PeriodicalId\":11139,\"journal\":{\"name\":\"Current Pharmacology Reports\",\"volume\":\"7 1\",\"pages\":\"1-14\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854874/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Pharmacology Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s40495-021-00250-z\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/2/3 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"Biochemistry, Genetics and Molecular Biology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Pharmacology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40495-021-00250-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/2/3 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0

摘要

审查目的:冠状病毒病-2019(COVID-19)是近代史上从未见过的全球性流行病,它给社会经济造成了深重的破坏,给人类带来了巨大的损失,并扰乱了医疗保健领域。尽管国际社会为遏制这一流行病做出了巨大努力,并启动了各种临床试验,但目前尚未证实任何有效的疗法:这篇综述强调了不同的传统治疗技术,以及纳米医学对严重急性呼吸系统综合症冠状病毒-2(SARS-CoV-2)的潜在贡献。雷米替韦和氯喹等药物的重新定位是实现安全治疗的快速过程,相关临床试验已确定了对 COVID-19 的效果。各种基于蛋白质的 SARS-CoV-2 候选疫苗已成功进入临床阶段,并取得了积极成果。大多数基于尖峰(S)蛋白抗原特性的自组装和金属纳米疫苗也是降低病毒负担的可接近、可行和有前景的技术。然而,对于基于纳米粒子(NP)的治疗,仍需要进行广泛的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Recent Advancement in SARS-CoV-2 Diagnosis, Treatment, and Vaccine Formulation: a New Paradigm of Nanotechnology in Strategic Combating of COVID-19 Pandemic.

Recent Advancement in SARS-CoV-2 Diagnosis, Treatment, and Vaccine Formulation: a New Paradigm of Nanotechnology in Strategic Combating of COVID-19 Pandemic.

Recent Advancement in SARS-CoV-2 Diagnosis, Treatment, and Vaccine Formulation: a New Paradigm of Nanotechnology in Strategic Combating of COVID-19 Pandemic.

Purpose of review: The coronavirus disease-2019 (COVID-19) is a global pandemic which has not been seen in recent history, leaving behind deep socioeconomic damages and huge human losses with the disturbance in the healthcare sector. Despite the tremendous international effort and the launch of various clinical trials for the containment of this pandemic, no effective therapy has been proven yet.

Recent findings: This review has highlighted the different traditional therapeutic techniques, along with the potential contribution of nanomedicine against the severe acute respiratory syndrome corovirus-2 (SARS-CoV-2). Repositioning of the drugs, such as remdesivir and chloroquine, is a rapid process for the reach of safe therapeutics, and the related clinical trials have determined effects against COVID-19. Various protein-based SARS-CoV-2 vaccine candidates have successfully entered clinical phases, determining positive results. The self-assembled and metallic nanovaccines mostly based on the antigenic properties of spike (S) protein are also approachable, feasible, and promising techniques for lowering the viral burden.

Summary: There are number of NP-based diagnostic systems have been reported for coronaviruses (CoVs) and specifically for SARS-CoV-2. However, extensive studies are still necessary and required for the nanoparticle (NP)-based therapy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current Pharmacology Reports
Current Pharmacology Reports Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
9.30
自引率
0.00%
发文量
35
期刊介绍: Current Pharmacology Reports will: publish cutting-edge reviews on subjects pertinent to all aspects of pharmacology, including drug discovery and development.provide incisive, insightful, and balanced contributions from international leading experts.interest a wide readership of basic scientists and translational investigators in academia and in industry. The Current Pharmacology Reports journal accomplishes its goal by appointing international authorities to serve as Section Editors in key subject areas, such as: epigenetics and epigenomics, chemoinformatics and rational drug design and target discovery, drug delivery and biomaterial, pharmacogenomics and molecular targets and biomarkers, chemical/drug/molecular toxicology, absorption, distribution, metabolism and elimination (ADME), pharmacokinetics (PK) and pharmacodynamics (PD), Modeling & Simulation (M&S) and pharmacometrics, and other related topics in pharmacology including neurology/central nervous system (CNS), cardiovascular, metabolic diseases, cancer, among others. Section Editors for Current Pharmacology Reports select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided. This journal publishes on a bi-monthly schedule.Please submit here: https://www.editorialmanager.com/phar/default.aspx
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信